miR‑26b inhibits isoproterenol‑induced cardiac fibrosis via the Keap1/Nrf2 signaling pathway Corrigendum in /10.3892/etm.2020.9412

Xiang,Shaohua; Li,Jing; Zhang,Zhengfu

doi:10.3892/etm.2020.8455

miR‑26b inhibits isoproterenol‑induced cardiac fibrosis via the Keap1/Nrf2 signaling pathway

Corrigendum in: /10.3892/etm.2020.9412

Authors:
- Shaohua Xiang
- Jing Li
- Zhengfu Zhang
View Affiliations

Affiliations: Department of Cardiothoracic Surgery, Dianjiang County Hospital of Traditional Chinese Medicine, Chongqing 408300, P.R. China, Department of Cardiothoracic Surgery, People's Hospital of Changshou, Chongqing 401220, P.R. China
Published online on: January 15, 2020 https://doi.org/10.3892/etm.2020.8455
Pages: 2067-2074
Copyright: © Xiang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

A critical event in cardiac fibrosis is the transformation of cardiac fibroblasts (CFs) into myofibroblasts. MicroRNAs (miRNAs) have been reported to be critical regulators in the development of cardiac fibrosis. However, the underlying molecular mechanisms of action of miRNA (miR)‑26b in cardiac fibrosis have not yet been extensively studied. In the present study, the expression levels of miR‑26b were downregulated in isoproterenol (ISO)‑treated cardiac tissues and CFs. Moreover, miR‑26b overexpression inhibited the cell viability of ISO‑treated CFs and decreased the protein levels of collagen I and α‑smooth muscle actin (α‑SMA). Furthermore, bioinformatics analysis and dual luciferase reporter assays indicated that Kelch‑like ECH‑associated protein 1 (Keap1) was the target of miR‑26b, and that its expression levels were decreased in miR‑26b‑treated cells. In addition, Keap1 overexpression reversed the inhibitory effects of miR‑26b on ISO‑induced cardiac fibrosis, as demonstrated by cell viability, and the upregulation of collagen I and α‑SMA expression levels. Furthermore, inhibition of Keap1 expression led to the activation of nuclear factor erythroid 2‑related factor 2 (Nrf2), which induced the transcriptional activation of antioxidant/detoxifying proteins in order to protect against cardiac fibrosis. Taken together, the data demonstrated that miR‑26b attenuated ISO‑induced cardiac fibrosis via the Keap‑mediated activation of Nrf2.

View Figures

View References

1	Molkentin JD, Bugg D, Ghearing N, Dorn LE, Kim P, Sargent MA, Gunaje J, Otsu K and Davis J: Fibroblast-specific genetic manipulation of p38 mitogen-activated protein kinase in vivo reveals its central regulatory role in fibrosis. Circulation. 136:549–561. 2017. View Article : Google Scholar : PubMed/NCBI
2	Segura AM, Frazier OH and Buja LM: Fibrosis and heart failure. Heart Fail Rev. 19:173–185. 2014. View Article : Google Scholar : PubMed/NCBI
3	Edgley AJ, Krum H and Kelly DJ: Targeting fibrosis for the treatment of heart failure: A role for transforming growth factor-β. Cardiovasc Ther. 30:e30–e40. 2012. View Article : Google Scholar : PubMed/NCBI
4	Espira L and Czubryt MP: Emerging concepts in cardiac matrix biology. Can J Physiol Pharmacol. 87:996–1008. 2009. View Article : Google Scholar : PubMed/NCBI
5	Fan D, Takawale A, Lee J and Kassiri Z: Cardiac fibroblasts, fibrosis and extracellular matrix remodeling in heart disease. Fibrogenesis Tissue Repair. 5:152012. View Article : Google Scholar : PubMed/NCBI
6	Barnes JL and Gorin Y: Myofibroblast differentiation during fibrosis: Role of NAD(P)H oxidases. Kidney Int. 79:944–956. 2011. View Article : Google Scholar : PubMed/NCBI
7	Weber KT, Sun Y, Tyagi SC and Cleutjens JP: Collagen network of the myocardium: Function, structural remodeling and regulatory mechanisms. J Mol Cell Cardiol. 26:279–292. 1994. View Article : Google Scholar : PubMed/NCBI
8	Swynghedauw B: Molecular mechanisms of myocardial remodeling. Physiol Rev. 79:215–262. 1999. View Article : Google Scholar : PubMed/NCBI
9	Romaine SP, Tomaszewski M, Condorelli G and Samani NJ: MicroRNAs in cardiovascular disease: An introduction for clinicians. Heart. 101:921–928. 2015. View Article : Google Scholar : PubMed/NCBI
10	Gurha P: MicroRNAs in cardiovascular disease. Curr Opin Cardiol. 31:249–254. 2016. View Article : Google Scholar : PubMed/NCBI
11	Li L, Bounds KR, Chatterjee P and Gupta S: MicroRNA-130a, a potential antifibrotic target in cardiac fibrosis. J Am Heart Assoc. 6(pii): e0067632017.PubMed/NCBI
12	Du W, Liang H, Gao X, Li X, Zhang Y, Pan Z, Li C, Wang Y, Liu Y, Yuan W, et al: MicroRNA-328, a potential anti-fibrotic target in cardiac interstitial fibrosis. Cell Physiol Biochem. 39:827–836. 2016. View Article : Google Scholar : PubMed/NCBI
13	Chen L, Ji Q, Zhu H, Ren Y, Fan Z and Tian N: miR-30a attenuates cardiac fibrosis in rats with myocardial infarction by inhibiting CTGF. Exp Ther Med. 15:4318–4324. 2018.PubMed/NCBI
14	Qin RH, Tao H, Ni SH, Shi P, Dai C and Shi KH: microRNA-29a inhibits cardiac fibrosis in Sprague-Dawley rats by downregulating the expression of DNMT3A. Anatol J Cardiol. 20:198–205. 2018.PubMed/NCBI
15	Wei C, Kim IK, Kumar S, Jayasinghe S, Hong N, Castoldi G, Catalucci D, Jones WK and Gupta S: NF-κB mediated miR-26a regulation in cardiac fibrosis. J Cell Physiol. 228:1433–1442. 2013. View Article : Google Scholar : PubMed/NCBI
16	Han M, Yang Z, Sayed D, He M, Gao S, Lin L, Yoon S and Abdellatif M: GATA4 expression is primarily regulated via a miR-26b-dependent post-transcriptional mechanism during cardiac hypertrophy. Cardiovasc Res. 93:645–654. 2012. View Article : Google Scholar : PubMed/NCBI
17	Niture SK, Khatri R and Jaiswal AK: Regulation of Nrf2-an update. Free Radic Biol Med. 66:36–44. 2014. View Article : Google Scholar : PubMed/NCBI
18	Baird L and Dinkova-Kostova AT: The cytoprotective role of the Keap1-Nrf2 pathway. Arch Toxicol. 85:241–272. 2011. View Article : Google Scholar : PubMed/NCBI
19	Shi H, Shi A, Dong L, Lu X, Wang Y, Zhao J, Dai F and Guo X: Chlorogenic acid protects against liver fibrosis in vivo and in vitro through inhibition of oxidative stress. Clin Nutr. 35:1366–1373. 2016. View Article : Google Scholar : PubMed/NCBI
20	Cheresh P, Kim SJ, Tulasiram S and Kamp DW: Oxidative stress and pulmonary fibrosis. Biochim Biophys Acta. 1832:1028–1040. 2013. View Article : Google Scholar : PubMed/NCBI
21	Wang LP, Fan SJ, Li SM, Wang XJ, Gao JL and Yang XH: Oxidative stress promotes myocardial fibrosis by upregulating KCa3.1 channel expression in AGT-REN double transgenic hypertensive mice. Pflugers Arch. 469:1061–1071. 2017. View Article : Google Scholar : PubMed/NCBI
22	Wu Y, Liu Y, Pan Y, Lu C, Xu H, Wang X, Liu T, Feng K and Tang Y: MicroRNA-135a inhibits cardiac fibrosis induced by isoproterenol via TRPM7 channel. Biomed Pharmacother. 104:252–260. 2018. View Article : Google Scholar : PubMed/NCBI
23	Tao H, Zhang JG, Qin RH, Dai C, Shi P, Yang JJ, Deng ZY and Shi KH: LncRNA GAS5 controls cardiac fibroblast activation and fibrosis by targeting miR-21 via PTEN/MMP-2 signaling pathway. Toxicology. 386:11–18. 2017. View Article : Google Scholar : PubMed/NCBI
24	Lu J, Wang QY, Zhou Y, Lu XC, Liu YH, Wu Y, Guo Q, Ma YT and Tang YQ: AstragalosideIV against cardiac fibrosis by inhibiting TRPM7 channel. Phytomedicine. 30:10–17. 2017. View Article : Google Scholar : PubMed/NCBI
25	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
26	Periasamy S, Chen SY and Liu MY: The study of ISO induced heart failure rat model, Exp Mol Pathol. 2010;88:299-304. Exp Mol Pathol. 90:842011. View Article : Google Scholar : PubMed/NCBI
27	Artaud-Macari E, Goven D, Brayer S, Hamimi A, Besnard V, Marchal-Somme J, Ali ZE, Crestani B, Kerdine-Römer S, Boutten A and Bonay M: Nuclear factor erythroid 2-related factor 2 nuclear translocation induces myofibroblastic dedifferentiation in idiopathic pulmonary fibrosis. Antioxid Redox Signal. 18:66–79. 2013. View Article : Google Scholar : PubMed/NCBI
28	Zhou XL, Xu H, Liu ZB, Wu QC, Zhu RR and Liu JC: miR-21 promotes cardiac fibroblast-to-myofibroblast transformation and myocardial fibrosis by targeting Jagged1. J Cell Mol Med. May 28–2018.(Epub ahead of print).
29	Icli B, Wara AK, Moslehi J, Sun X, Plovie E, Cahill M, Marchini JF, Schissler A, Padera RF, Shi J, et al: MicroRNA-26a regulates pathological and physiological angiogenesis by targeting BMP/SMAD1 signaling. Circ Res. 113:1231–1241. 2013. View Article : Google Scholar : PubMed/NCBI
30	Köhler UA, Kurinna S, Schwitter D, Marti A, Schäfer M, Hellerbrand C, Speicher T and Werner S: Activated Nrf2 impairs liver regeneration in mice by activation of genes involved in cell-cycle control and apoptosis. Hepatology. 60:670–678. 2014. View Article : Google Scholar : PubMed/NCBI
31	Gambhir L, Checker R, Thoh M, Patwardhan RS, Sharma D, Kumar M and Sandur SK: 1,4-Naphthoquinone, a pro-oxidant, suppresses immune responses via KEAP-1 glutathionylation. Biochem Pharmacol. 88:95–105. 2014. View Article : Google Scholar : PubMed/NCBI
32	Civantos E, Bosch E, Ramirez E, Zhenyukh O, Egido J, Lorenzo O and Mas S: Sitagliptin ameliorates oxidative stress in experimental diabetic nephropathy by diminishing the miR-200a/Keap-1/Nrf2 antioxidant pathway. Diabetes Metab Syndr Obes. 10:207–222. 2017. View Article : Google Scholar : PubMed/NCBI
33	Yang JJ, Tao H, Hu W, Liu LP, Shi KH, Deng ZY and Li J: MicroRNA-200a controls Nrf2 activation by target Keap1 in hepatic stellate cell proliferation and fibrosis. Cell Signal. 26:2381–2389. 2014. View Article : Google Scholar : PubMed/NCBI